Liposomal corticosteroids for the treatment of inflammatory disorders and cancer

JOURNAL OF CONTROLLED RELEASE

卷:190

Review

Ozbakir, Burcin¹  Crielaard, Bart J.^1,2  Metselaar, Josbert M.⁴  Storm, Gert^1,4  Lammers, Twan^1,3,4 

[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3584 CG Utrecht, Netherlands

[2] Weill Cornell Med Coll, Dept Pediat Hematol Oncol, New York, NY 10021 USA

[3] Rhein Westfal TH Aachen, Helmholtz Inst Biomed Engn, Dept Expt Mol Imaging, D-52074 Aachen, Germany

[4] Univ Twente, MIRA Inst Biomed Engn & Tech Med, Dept Controlled Drug Delivery, NL-7500 AE Enschede, Netherlands

关键词: Liposomes;    Corticosteroids;    Nanomedicine;    Inflammation;    Cancer;   

DOI  :  10.1016/j.jconrel.2014.05.039

来源: Elsevier

【 摘 要 】

Glucocorticoids (GC) are known for their potent immunosuppressive and anti-inflammatory properties. As a consequence, they have been extensively used for the treatment of many different diseases. Prolonged and, or high-dose GC therapy, however, generally comes with severe side effects, resulting not only from their very diverse mechanism(s) of action, but also from their relatively poor biodistribution. Drug delivery systems, and in particular liposomes, have been extensively used to enhance the biodistribution and the target site accumulation of GC, and to thereby improve the balance between their efficacy and their toxicity. Many different types of Liposomes have been employed, and both local and systemic treatments have been evaluated. We here summarize the progress made in the use of liposomal GC formulations for the treatment of asthma, rheumatoid arthritis, multiple sclerosis and cancer, and we show that the targeted delivery of GC to pathological sites holds significant clinical potential, (C) 2014 Elsevier B.V. All rights reserved.

【 授权许可】

Free